Report lays out blueprint for achieving Organon’s purpose and business imperatives to help women and girls achieve their promise through better health

  • Launch of Her Promise ESG platform creates a framework by which the company will advance innovation and progress in women’s health and contribute to UN Sustainable Development Goals  
  • Organon Her Promise Access Initiative aims to provide 100 million girls and women in low -and –middle –income countries with affordable access to contraceptive options by 20301.
  • Grant to global NGO Women Deliver for their Young Leaders program and other advocacy work including support for young people around the world to advocate for and advance women’s health and gender equality

JERSEY CITY, N.J. – Organon (NYSE: OGN), a global women’s healthcare company, which employs 88 people in Australia, today announced the publication of its inaugural Environmental, Social, and Governance (ESG) Report (attached) for 2021. The global report introduces the company’s ESG platform, known as Her Promise, and details how the company is working to help women and girls achieve the full potential of their promise through better health. The publication of the ESG Report and launch of Her Promise coincides with Organon’s one year anniversary and reflects the company’s vision to create a better and healthier every day for every woman around the world.

As the only global women’s healthcare company of its kind, Organon is well positioned to help address several current and growing women’s health challenges. For example, worldwide modelling estimates that nearly half of all pregnancies worldwide – about 121 million in total – are unintended2. Through Her Promise, Organon is making focused investments and forming strategic partnerships with the goal of introducing and expanding access to health solutions that improve women’s health and advance gender equity, inside and outside the company.

In Australia, unintended pregnancy is also a common occurrence, with one in four women reporting they have had an unintended pregnancy in the past 10 years3. The rates are even higher in rural and remote locations, with women in rural areas 1.4 times more likely to experience an unintended pregnancy4.  For younger people aged 18-32 years, the rate is higher, with 40.8 per cent reporting an unintended first pregnancy4.

“In just one year, Organon has made considerable progress in addressing gender-related disparities in health by listening to women and investing in areas where high unmet needs exist. Since our launch, we have focused on treatment gaps that need to be addressed, like unintended pregnancy, fertility, post-partum hemorrhage, pre-term labor, endometriosis and bacterial vaginosis, and will continue to strive to deliver innovation, improve access and expand choice for treatments areas that uniquely or disproportionately affect women,” says Kevin Ali, Organon’s Chief Executive Officer. “The goals stated in our first ESG Report create a roadmap for the future of how we will continue to propel forward and partner to transform the current women’s health environment.”

“Here in Australia, we are proud of the impact we are already having empowering Australians to decide if, when and how they have children through our contraceptive and fertility business units,” Organon Australia Managing Director Nirelle Tolstoshev said. “Our commitment to making a positive social impact extends beyond our portfolio, and we are in the final stages of determining our local not-for-profit partnerships, with a focus on advancing her health and gender equity, and tackling climate change. We are also using our voice to amplify calls for Reconciliation and recently marked National Sorry Day by signing the Uluru Statement from the Heart.”

On its one-year anniversary, Organon is making the following goals to achieve Her Promise:

  • To improve access to low-cost contraceptives in 69 of the world’s least developed countries. Through the Organon Her Promise Access Initiative, Organon is working with global organisations to provide family planning information, education and access to low-cost contraceptive options. Organon’s goal is to provide 100 million girls and women in low -and –middle –income countries with affordable access to contraceptive options by 20301.
  • To redefine and harness innovation in women’s health. Organon will dedicate a majority of its pre-clinical and clinical development activity toward the unmet health needs of women. Organon has already begun with development activities in high unmet need areas including postpartum hemorrhage, endometriosis, and pre-term labor.
  • Expand access to treatment options that improve her health and help secure her promise. Working together with global partners, Organon plans to expand access to treatment options for post-partum hemorrhage in women, in both developed and developing markets. We will also seek to help address affordability of fertility treatments and access to education to decrease the unmet medical need in fertility.
  • Achieve balanced gender representation through all levels of Organon globally by 2030 and pay equity. Organon has had a strong start by launching with a Board of Directors that consists of accomplished individuals with exceptional skills and expertise, and also represents gender and racial diversity. Currently, Organon’s Board is the most diverse healthcare board on the S&P 500.

Organon in Australia has already achieved gender equity at all levels of the business, and also completed and actioned a pay equity review within the first six months of operation.

  • Aim to support the transition to a low carbon economy, with an ambition to achieve net zero greenhouse gas emissions. We also aim to integrate water stewardship and circular economy principles into our business models. The report details concrete short- and mid-terms actions we will take to meet these long-term ambitions.
  • Uphold the highest levels of ethics and integrity throughout its business.

As part of its commitment to advancing gender equity through Her Promise, Organon in Australia is forming collaborative partnerships with not-for-profit organisations to make a positive impact by advancing women’s health, gender equity and tackling climate change.

“The Board is committed to achieving both Organon’s business goals as well as contributing to societal goals, and to continuing to drive the company’s ESG strategy,” says Carrie Cox, Board Chairman. “We are pleased to be in a position to publish a comprehensive ESG report just one year after the company’s establishment and highlight our purpose and goals in improving the health of women and girls.

For more details on Organon’s ESG strategy, priorities, and initiatives, please see the full 2021 ESG Report attached. 

You can access further information about Organon Australia at https://www.organon.com/australia/ and connect with us on LinkedIn.

About Organon

Organon is a global healthcare company with a focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialise their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,300 employees with headquarters located in Jersey City, New Jersey.

Copyright © (2022) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110096. First issued June 2022.

###

  1. Data on file: Organon FY2021 ESG Report. Published June 2022. Page 14
  2. Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6)
  3. Taft et al (2018). Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes. Med J Aust, 209 (9): 407-408
  4. Rowe et al. (2015). Prevalence and distribution of unintended pregnancy: the Understanding Fertility Management in Australia National Survey. ANZJPH, 40(2):104-9.

Organon (NYSE: OGN) – a company focused on the health and wellbeing of women has marked National Sorry Day by adding its signature to support the Uluru Statement from the Heart, which calls for the establishment of a First Nations Voice in the Constitution and a Makarrata Commission on agreement-making and truth-telling between Aboriginal and Torres Strait Islander peoples and governments.

Nirelle Tolstoshev, managing director of Organon in Australia said, “We launched Organon globally with a promise to listen to and act on women’s experiences to address the challenges in women’s health. The Uluru Statement from the Heart also calls for First Nations People’s voices to be heard, and we believe that action is needed to address the inequities which continue to be experienced by Aboriginal and Torres Strait Island peoples.

“The Uluru Statement represents an invitation for all Australians to come together in a national dialogue that will help to positively shape our national identity, and by signing the Uluru Statement from the Heart, we are clearly signalling that First Nations voices matter and should be heard.

Organon was established and listed on the New York Stock Exchange in June 2021. “One of the early conversations we had with our Founders in Australia was about reconciliation with First Nations people and developing a Reconciliation Action Plan, which we are currently working towards. In the meantime, we wanted to show our commitment by signing the Statement from the Heart on this important day.

“We encourage other pharmaceutical and healthcare companies across the country to join us in this important conversation,” Tolstoshev concluded.

To learn more about Organon, please visit http://www.organon.com/australia and connect with us on LinkedIn.
About Organon
Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

Organon launches Circle In as a new benefit for managers and employees, continuing its commitment to a ‘people first’ culture.

Organon ANZ is the first pharmaceutical company to partner with Circle In – a digital platform that helps employees and their managers support, grow and connect with caregivers in the workplace, by providing discreet support, expert advice and facilitates meaningful connections with teams and individual employees, accessible at the time when it is needed.

The on-demand content is already proving to be a useful resource for Organon’s employees and managers.  Launched just one month ago in February 2022, 35% of Organon employees have already registered on the platform and spent time interacting with the videos and articles. The most popular areas for investigation include navigating career; menopause; single parent happiness; and support for neurodiverse children.

“At Organon, we have created a People First culture, where every employee can bring their best self to work. We do this by supporting each founder – as a team member, as a parent and caregiver, and as managers of parents and caregivers, said Sophie Althans, HR Director Organon ANZ.

“It is important that we continue to evolve our employee experience, and providing resources that are relevant at each stage in our employees’ life journey at the right time is an important part of respecting and supporting the diversity of each of our founders. We hope the addition of these discreet and accessible resources to Organon’s comprehensive suite of Employee Benefits encourages honest conversations, provides thoughtful support and expert advice to help our managers and employees to maintain meaningful connections.”

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com/australia and connect with us on LinkedIn.  

For more information:

MESHLIN KHOURI

meshlin.khouri@organon.com

+61 447 279 553

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

International Women’s Day has, since its inception, called upon governments, businesses, and the wider community to reflect on issues of gender parity and inequality. A day to consider and accelerate efforts towards gender equity.

And while much has been spoken about these inequalities from economic, social, health, and physical security, far less action has been taken to address these issues in a meaningful way.

Too often businesses shrug off these issues as a matter for government. And whilst it’s true that government certainly plays a role in paving a way for a more equitable tomorrow for women – it’s also the case that businesses can do more than host breakfasts and put on morning teas.

We need to action what we speak about at these luncheons and conferences. Walk the talk, so to speak.

There is ample evidence both internationally and locally that the current COVID-19 pandemic is unraveling women’s hard-fought for gains in workplaces. Many women are now significantly more burned out than ever, even more than men which can take a huge toll on their physical and mental health1.

McKinsey recently predicted in their 2020 Women in the Workplace study2 that the global pandemic could set women back half a decade as they consider leaving the workforce for good. Organisations losing female leaders’ risk unwriting the years of progress towards gender equality.

______________________________

1 McKinsey & Company: Women in the Workplace 2021. https://www.mckinsey.com/featured-insights/diversity-and-inclusion/women-in-the-workplace. Page 5. Accessed: 02 February 2022

2 McKinsey & Company: Women in the Workplace 2021. https://www.mckinsey.com/featured-insights/diversity-and-inclusion/women-in-the-workplace. Page 5. Accessed: 02 February 2022

The Jean Hailes’ Women’s Health Survey 2020 Snapshot3 reports that 31.7% of women aged 25 – 44 did not have enough time to attend health check appointments, and one in four could not get an appointment when they needed one.

A recent online survey of 10,000 Australian women conducted between February and April 2021 by Australia’s National Research Organisation for Women’s Safety4, found that COVID has had an impact on women’s personal and professional lives, as well as that of her family.

One in three women (31 per cent) in the survey had been laid off, lost their job or had to take a pay cut or reduce hours, in the first 12 months of the pandemic. As a result, women reported being unable to pay bills on time, needing to pawn or sell something, going without needed medical or dental treatment, and skipping meals5.

I am proud to lead Organon in Australia, we are a global health care company that is united in our drive to better support the health of women, both within our company and around the globe.  We invest in medicines and innovations that support the distinct healthcare needs of women across her healthcare lifecycle.

We know that when women are healthier the whole community benefits and that a woman’s health is impacted not just by her physical wellbeing but by her education; culture; career; economic and physical security, and mental wellbeing.

This International Women’s Day, we have moved away from reflection to tangible action in addressing the health inequities exacerbated by COVID-19. We have given every employee around the globe a paid day off on International Women’s Day to allow them to attend to their own health needs, or the needs of women they care for.

We believe that by empowering women to put their health needs at the top of the priority list is part of the change we need to drive to increase gender equity in all aspects of their lives.  Especially as the pandemic continues to limit women’s ability to take care of themselves, we are proud to show our commitment to meeting women’s unmet health needs today and into the future.

I know that by improving the understanding of women’s health needs that we are one step closer to closing the inequity gap. We have urged other organisations to also take practical steps in improving workplace culture for women and join us in this mission and be part of the solution.

______________________________

3 Jean Hailes Women’s Health Survey 2020. Women’s Health Survey 2020 | Jean Hailes. Accessed: 02 February 2022

4 Australia’s National Research Organisation for Women’s Safety (ANROWS). Economic insecurity and intimate partner violence in Australia during the COVID-19 pandemic:  Economic-insecurity-and-IPV-during-the-C19-RR2.pdf (netdna-ssl.com). Page 8. Accessed: 02 February 2022

5 Australia’s National Research Organisation for Women’s Safety (ANROWS). Economic insecurity and intimate partner violence in Australia during the COVID-19 pandemic:  Economic-insecurity-and-IPV-during-the-C19-RR2.pdf (netdna-ssl.com). Page 8. Accessed: 02 February 2022

Nirelle Tolstoshev
Managing Director
Organon Australia and New Zealand

Copyright © (2022) Organon group of companies. All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113.AU-NON-110077 First issued March 2022.

As the COVID-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health in Australia

Sydney, Australia. February 3, 2022 — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on March 8 as a day to recognise the growing health disparities women face that have been exacerbated by the COVID-19 pandemic1. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and is starting with its own employees, including the almost 100 in Organon Australia, by providing paid time off this year for all employees to attend to their own health needs. The company invites organisations in Australia and across the globe to join in raising awareness of the inequity in women’s health and to adopt initiatives that help women prioritise their health.

Women have worked hard to advance in the workplace, but the pandemic is unraveling these hard-fought gains. Many women are now significantly more burned out than ever, even more than men1 — which can take a huge toll on their physical and mental health. The Jean Hailes’ Women’s Health Survey 2020 Snapshot reports that 31.7% of women aged 25 – 44 did not have enough time to attend health check appointments, and one in four could not get an appointment when they needed one2.

“Organon launched with a commitment to listen to the needs of women and as part of our research, we learned that women are finding it harder than ever to make the time to care for even their most basic health needs,” said Kevin Ali, chief executive officer, Organon. “As a company investing in innovation to improve women’s health, I felt a responsibility to help address this within our own global community of almost 9,500 employees. This year, the symbolic action we are taking is to encourage all our people to spend this day off to make a commitment to their own health or the health of the women in their lives, whether that’s going to the doctor, taking stock of their own wellbeing or reflecting on how to make a change.”

“We believe healthy women are the backbone of a thriving, stable and resilient society and when she is healthy, she prospers and so does her community, her society for generations to come. The Australian Federal Government’s National Women’s Health Strategy 2020 – 20303 recognises the gaps in health outcomes and key health inequities exists for women and girls, and seeks to address these”, said Nirelle Tolstoshev, managing director for Organon Australia.

An online survey of 10,000 Australian women conducted between February and April 2021 by Australia’s National Research Organisation for Women’s Safety, found that COVID has had an impact on women’s personal and professional lives, as well as that of her family4.

One in three women (31 per cent) in the survey had been laid off, lost their job or had to take a pay cut or reduce hours, in the first 12 months of the pandemic. As a result, women reported being unable to pay bills on time, needing to pawn or sell something, going without needed medical or dental treatment, and skipping meals. This has a profound impact not only on women, but also their families and their communities.

This is what Organon is hoping to change, and we are asking others to join in the effort to improve women’s health.

“We foster a People First culture to support our people, our customers and the communities in which we live and work. Empowering women to put their health needs at the top of the priority list is part of the change we need to drive to increase gender equity in all aspects of their lives,” continued Tolstoshev.  “Especially as the pandemic continues to limit women’s ability to take care of themselves, we are proud to show our commitment to meeting women’s unmet health needs today and into the future.”

We believe that by improving the understanding of women’s health needs, we are one step closer to closing the inequity gap. Organon urges all organisations to join in this mission and be part of the solution. Visit hereforherhealth.com/make-time to learn more.

About Organon

Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK) known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Copyright © (2022) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113.

AU-NON-110002. First issued February 2022.

To learn more about Organon, please visit https://organon.com/australia/

REFERENCES:

1.McKinsey & Company 
Women in the Workplace 2021 
https://www.mckinsey.com/featured-insights/diversity-and-inclusion/women-in-the-workplace
Accessed: 02 February 2022

2.Jean Hailes 
Women’s Health Survey 2020
Women’s Health Survey 2020 | Jean Hailes
Accessed: 02 February 2022

3.Australian Federal Government
National Women’s Health Strategy 2020 – 2030
National Women’s Health Strategy 2020–2030 | Australian Government Department of Health
Accessed: 02 February 2022

4.Australia’s National Research Organisation for Women’s Safety (ANROWS)
Economic insecurity and intimate partner violence in Australia during the COVID-19 pandemic: Economic-insecurity-and-IPV-during-the-C19-RR2.pdf (netdna-ssl.com)
Accessed: 02 February 2022

Organon now the only healthcare company to have dual membership of MA and GBMA

Just five months after our launch in June 2021, Organon has become members of both Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA), and is the only healthcare company in Australia to be members of both industry representative organisations.

“Organon Australia is proud to be members of both Medicines Australia as well as Generic and Biosimilar Medicines Association.  Our commitment is to the health and wellbeing of women, and we look forward to using our voice to advocate for access and innovative treatments to support a healthier every day for every woman,” said Luke Cornish, Access and External Affairs director.

“This is a very important time for the pharmaceutical industry, with Australians recognising the value that medicines and our industry brings. Our clear and dedicated focus on the health of women is at the centre of everything we do, and membership of both MA and GBMA means that we can focus on making a positive contribution toward a healthcare environment which offers patient’s choice, and supports innovation and access in medicines by helping to manage the healthcare budget.”

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

Copyright © (2021) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.

Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace.

Organon’s commitment to a ‘people first’ culture as the foundation for its business has been recognised by Family Friendly Workplaces, with its recent certification as a Family Inclusive Workplace.  Family Friendly Workplaces is a joint initiative of Parents at Work and UNICEF Australia, and measures workplaces against standards developed to encourage employers to benchmark their own internal policies against nationally recognised best practices.

One of our priorities when we formed was to give our Founders a voice through employee resource groups (ERGs).  The Families@Work ERG were keen to benchmark how Organon was positioned in living up to its commitment to people first, as well as to explore opportunities to consistently aim for ongoing improvement.

Tim Cogin, Director Fertility, Organon ANZ, is the sponsor for the Families@Work ERG, commented, “We are incredibly proud that we have been able to achieve certification as a Family Friendly Workplace in our first four months since establishing as a company.  We are in unique times of high stress, and never before has work and family life been so closely integrated. We always want our people to feel good about balancing their work priorities with their family priorities. We know that family comes first, and it is important that workplaces reflect this and adapt accordingly.”

Organon recognises the need to support families in all their forms and has policies to bring this to life for every employee. Initiatives such as the Gift of Time which allowed time off for parents who home-schooled children during the COVID lockdowns and encouraged all employees to take time during the workday to focus on their own health and wellbeing; Focus Fridays which discourages meetings on Fridays and enables a 3pm finish, so that our Founders can focus on deep thinking and completing work without the pressure of meetings; and a unique Principles-based Work @ Organon approach to office attendance are demonstrations of our recognition  that families come in all shapes and sizes and vary depending on life stages.  We also have plans to continue to evolve our offering over time, and with input from our Founders.

Sophie Althans, Director HR with Organon ANZ shares her perspective on the impact of supporting Founders in all their unique requirements.  “I’m proud of the unique people first culture that we actively foster in every decision we make.  Embracing flexibility and being open with how our teams work and evolve has a significant correlation with our strong employee engagement across a range of measures. We continue to foster an agile environment in which all Founders have a sense of belonging and bring their valuable diverse perspectives in wholeheartedly embracing Organon’s values.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Growing a business with a commitment to listen to women to understand her health needs requires different thinking and approaches

Just four months since its launch as the only global company of its size focused on women’s health, Organon in Australia continues to invest in people to deliver on its focus on women’s health through its portfolios of women’s contraception and fertility, biosimilars and established brands.

One unique approach has been to attract people from outside of the traditional pharma sector for fresh eyes and fresh ideas.  In just four short months, Organon has grown its employee founder base with six senior positions filled from diverse industries including the construction, FMCG, Medical Devices, automotive and political sectors.

“We have brought in external people that are non-pharma, and already we’re seeing new perspectives, new reference points and new approaches – opening our lateral and strategic thinking. We embrace the different insights and energy and we’re saying don’t wait to settle in, we want to hear your ideas now,” said Nirelle Tolstoshev, Managing Director, Organon ANZ.

Attracting the best people to support Organon’s strategy to lead and evolve as a progressive, future fit and dynamic organisation is proving to be a successful part of Organon’s success, including two additions to the Organon Leadership Team, with Sophie Althans commencing as HR Director and Mark Coleman taking the role of Strategy and Organisational Development Lead.

Sophie is a member of both the ANZ Leadership Team and the Regional HR Leadership Team.  She will oversee the continuing development of Organon ANZ’s people and culture of engagement to support short term business execution and long-term transformation. Sophie has a wealth of experience in supporting organisations to achieve their business priorities through driving effective talent strategies. As well as expertise in the pharmaceutical sector, Sophie has also worked in Medical Devices, Supply Chain and FMCG.

Mark Coleman joins in a novel role specifically designed to lead Organon’s organisational development strategy.  Mark has over 20 years’ experience in healthcare, and is passionate about helping teams thrive through creating environments that enable learning, reflection and growth.

In an early indication of the commitment to a culture of people first, entrepreneurship, and a mindset focused on future requirements, Mark will support the organisation to realise the company vision and values.

“With their deep expertise in people, processes to foster learning, business excellence, and continuous improvement for growth, I am confident that Sophie and Mark will make great contributions to our business,” said Nirelle Tolstoshev.

Organon in Australia is one of the few markets globally to have all three core pillars of Women’s Health, Biosimilars and Established Brands.

To learn more about Organon, please visit Home | Organon or Organon ANZ on LinkedIn

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Building on vision to create a better and healthier every day for every woman, Organon launches video to challenge and help reduce stigma of global public health issue

SYDNEY – Organon (NYSE: OGN), a global women’s health company, is hoping to address the staggering rates of unplanned pregnancies around the world by launching a video to raise awareness and ignite a worldwide conversation around unplanned pregnancy.

Worldwide modelling estimates that unplanned pregnancy impacts approximately 121 million women each year.1 A 2019 study reported that globally, more than 1 billion women have a need for family planning, but for 270 million of them, that need for modern methods is unmet.2** Unplanned pregnancy can impact any woman anywhere – regardless of her social or economic background.

In Australia, one in four women had an unintended pregnancy in the past 10 years, and 30 per cent of unintended pregnancies ended in abortion.3 The rates are even higher in rural and remote locations, with women in rural areas are 1.4 times more likely to experience an unintended pregnancy.4  For younger people aged 18-32 years, 40.8 per cent reported an unintended first pregnancy.4

“While we have seen a lot of progress in the area of reproductive health, the rates of unplanned pregnancy continue to be high,” said Margie Austin, Women’s Health Business Director for

__________________________________

1 Bearak J, Painchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019. Lancet Glob Health. 2020;8(9):e1152-e1161. doi:10.1016/S2214-109X(20)30315-6

2 Kantorová V, Wheldon MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards meeting women’s contraceptive needs in 185 countries: A Bayesian hierarchical modelling study. PLoS Med 17(2): e1003026. https://doi.org/10.1371/journal.pmed.1003026

3 Taft et al (2018). Unintended and unwanted pregnancy in Australia: a cross-sectional, national random telephone survey of prevalence and outcomes. Med J Aust, 209 (9): 407-408

4 Rowe et al. (2015). Prevalence and distribution of unintended pregnancy: the Understanding Fertility Management in Australia National Survey. ANZJPH, 40(2):104-9.

**According to Kantorová et. al, modern methods of contraception include female and male sterilization, the intrauterine device (IUD), the implant, injectables, oral contraceptive pills, male and female condoms, vaginal barrier methods, the lactational amenorrhea method (LAM), emergency contraception and other modern methods such as the contraceptive patch or vaginal ring.

Organon Australia. “There is no better time than ahead of World Contraception Day to focus on empowering her through education, information, empathy and conversation to help reduce unplanned pregnancy.

General Practitioner with a special interest in women’s health, including contraception and menopause, Dr Meredith Frearson believes that contraception enables women to plan their path. “Today’s contraceptive options are wide and varied and I encourage all women to take the time to discuss their options with their health care providers.  Even in Australia many women may not be aware of the increasing range of options open to them and the additional benefits that some contraceptives can provide such as reducing menstrual loss and pain and assisting with changing needs as she reaches menopause.

“Contraceptive choices may well change across a woman’s reproductive lifespan. The introduction of several longer lasting methods has made a huge difference for many women who find having a reliable set and forget method to be a major bonus. I encourage women to embrace change and take the time to find out about their options from reliable sources,” Dr Frearson said.

“There is still so much we can do across our global and local communities to help raise awareness about unplanned pregnancy and work collectively towards lowering the rates,” Austin continued. “Today marks the beginning of a new conversation, one that is geared towards reducing the stigma of unplanned pregnancy and giving her the information she needs to make informed decisions.”

Organon invites women, their families, healthcare professionals, and policy makers to visit HereforHerHealth.com to share their perspectives on how to help reduce the rates of unplanned pregnancy and join us on a collective mission of having the conversation.

The video is available on HereforHerHealth.com where people are encouraged to share their perspective on how to help reduce unplanned pregnancy.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spin-off from Merck& Co., Kenilworth, NJ, USA (NYSE: MRK) known as MSD outside of the United States and Canada, focused on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey, USA.

For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon

Except for historical information herein, this news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, statements about management’s expectations about Organon’s future financial performance and prospects. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the ongoing COVID-19 pandemic and emergence of variant strains; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances; new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict its future financial results and performance; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

###

Women’s healthcare company Organon kicks off its global Organon Wellness Month in August, and the Australian subsidiary is making the most of the opportunity with a comprehensive program to promote employee health and wellbeing.

The month-long program aims to increase awareness and facilitate employee engagement focused on four pillars of wellness: physical; mental; professional; and social.

Based on these four pillars, Organon will reward employees who participate in the various programs offered, which include personalised health and wellness assessments; increase their daily physical activities; practice meditation techniques; or making time to develop and share hobbies.  Reward incentives to further prompt employee engagement include fitness and massage vouchers. This initiative is complimented with a previously established $250 Wellness Reimbursement Program which can be used to pay for a wide range of wellbeing programs and equipment.

With COVID-19 impacting the work, home and school environment, Organon has increased its focus on workplace flexibility and initiatives to foster a more sustainable working environment which includes encouraging all employees to take time during the workday to focus on their health as well as that of their family and community.

“Through this commitment and various initiatives that our people can choose from, we recognise and respect the diversity of each person’s needs. We believe that our employees will emerge from this period feeling more energised and with some fuel in the tank, versus being totally exhausted with no annual leave left. We just think that this is a more sustainable approach, ” said Nirelle Tolstoshev, managing director Organon ANZ.

About Organon

Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.

For more information, visit www.organon.com and connect with us on LinkedIn and Instagram.

Forward-Looking Statement of Organon & Co., Jersey City, N.J., USA

This news release of Organon & Co. (the “company”) may include “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will” or words of similar meaning. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov).

Copyright © (2021) Organon group of companies.  All rights reserved.

Organon Pharma Pty Ltd. Building A, Level 3, 26 Talavera Rd, Macquarie Park, NSW 2113. AU-NON-110002. First issued June 2021.